<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               <BR>                  WARNING: DERMATOLOGIC TOXICITY and INFUSION REACTIONS<BR>               <BR>               <BR>                  <BR>                     <BR>                        Dermatologic Toxicity: Dermatologic toxicities occurred in 89% of patients and were severe (NCI-CTC grade 3 and higher) in 12% of patients receiving Vectibix monotherapy [see Dosage and Administration (<BR>                        <BR>                           2.1), Warnings and Precautions (5.1), and Adverse Reactions (6.1)].<BR>                     <BR>                  <BR>                  <BR>                     <BR>                        Infusion Reactions:<BR>                     <BR>                      Severe infusion reactions occurred in approximately 1% of patients. Fatal infusion reactions occurred in postmarketing experience [see Dosage and Administration (2.1), Warnings and Precautions (5.2), and Adverse Reactions (6.1, 6.3)].<BR>                  <BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        <BR>                           WARNING: DERMATOLOGIC TOXICITY and INFUSION REACTIONS<BR>                        <BR>                        <BR>                           See full prescribing information for complete boxed warning.<BR>                        <BR>                           Dermatologic toxicities were reported in 89% of patients and were severe in 12% of patients receiving monotherapy. (2.1, 5.1, 6.1)<BR>                           Severe infusion reactions occurred in approximately 1% of patients. Fatal infusion reactions occurred in postmarketing experience. (2.1, 5.2, 6.1, 6.3)<BR>                        <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>